Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Aurinia Pharmaceuticals (AUPH) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 15, 2024, might help the stock move higher if these key nu ...

WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSXV:KNE, OTCQB:KNBIF) (the "Company", "Kane" or "Kane Biotech") announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the "Meeting") to consider the election of Dr. Robert Huizinga as an additional director of the Company. The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course. Dr. Huizinga is currently the principa ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Farzin Haque - Jefferies Joseph Schwartz - Leerink Partners Olivia Brayer - Cantor Fitzgerald Justin Kim - Oppenheimer and Company Ed Arce - HC Wainwright Sahil Dhingra - RBC Capital Markets David Martin - Bloom Burton Operator Greetings. Welco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------|------------------ ...

Financial Data and Key Metrics Changes - Aurinia Pharmaceuticals reported net product revenues of $41.1 million for Q2 2023, a 46% increase compared to Q2 2022 and a 20% increase over Q1 2023, bringing year-to-date revenues to $75.4 million, up over 52% from the same period in 2022 [5][21] - Total net revenue for Q2 2023 increased 47% to $41.5 million from $28.2 million in Q2 2022, and for the six months ended June 30, 2023, total net revenue increased 52% to $75.9 million from $49.8 million in the prior year [21][22] - The company recorded a net loss of $11.5 million or $0.08 per share for Q2 2023, compared to a net loss of $35.5 million or $0.25 per share for Q2 2022 [28] Business Line Data and Key Metrics Changes - The number of patient start forms (PSFs) totaled 451 in Q2 2023, a 10% increase over Q2 2022, with a conversion rate of 89% from PSFs to therapy, marking an all-time high [14][15] - The 12-month persistency rate for patients on LUPKYNIS improved from 51% to 54% in Q2 2023, indicating better retention [16] Market Data and Key Metrics Changes - The company has seen significant launch momentum for LUPKYNIS outside the U.S., with launches in Germany, Austria, Sweden, Finland, and Norway, and recent approvals in Switzerland, the U.K., and Italy [18] - The awareness campaign "Get Uncomfortable" reached over 750 million people, significantly increasing patient engagement and education [8] Company Strategy and Development Direction - Aurinia's strategy focuses on three main areas: driving patient awareness, clinically differentiating LUPKYNIS, and ensuring patient access to therapy [7] - The company is increasing its net product revenue guidance for 2023 from $135 million to $155 million to a new range of $150 million to $160 million [17] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of seasonality on patient flow during summer months but expressed confidence in returning to growth patterns in Q3 and Q4 [33][35] - The company is actively exploring strategic alternatives, including potential sales, in response to shareholder requests, emphasizing a commitment to fiduciary responsibilities [59][60] Other Important Information - Aurinia had cash and equivalents of $350.7 million as of June 30, 2023, down from $389.4 million at the end of 2022, primarily due to investments in commercialization and R&D [20][21] - The company is on track to file an IND for AUR200 by the end of the year and is advancing its lupus nephritis registry [17][18] Q&A Session Summary Question: What strategies are in place to mitigate seasonality impacts? - Management noted that summer months typically see a dip in patient flow due to asymptomatic conditions and staff vacations, but they are implementing targeted marketing initiatives to maintain patient engagement [33][35] Question: Will the biopsy data be submitted to the FDA? - Management confirmed that they have submitted a package of data to the FDA, including biopsy data, but a timeline for label updates is still under negotiation [37][39] Question: What are the underlying drivers for the recent revenue guidance increase? - Management highlighted that metrics such as patient conversion rates and persistency have reached all-time highs, contributing to revenue growth despite a slight decline in PSFs [41][42] Question: What proportion of prescribers are repeat prescribers? - Management did not provide specific percentages but emphasized the importance of increasing both the number of prescribers and the depth of prescribing [69] Question: What are patients saying about remaining on therapy longer? - Management indicated that patient feedback is generally positive, with ongoing efforts to enhance patient education and support for long-term therapy adherence [70]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------|----------------------- ...

Start Time: 08:30 January 1, 0000 9:27 AM ET Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Peter Greenleaf - President and CEO Joe Miller - CFO Jamie Harrell - Head of IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Farzin Haque - Jefferies Stacy Ku - TD Cowen Justin Kim - Oppenheimer Ed Arce - H.C. Wainwright David Martin - Bloom Burton Will Soghikian - SVB Securities Sahil Dhingra - RBC Capital Markets Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------|---------------------- ...

Corporate Presentation Cautionary statement regarding forward-looking information Certain statements made in this slide presentation may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable United States securities law. These forward-looking statements or information include but are not limited to statements or information with respect to: Aurinia’s estimates as to its unaudited net revenues and produc ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Jamie Harrell - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joseph Miller - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jefferies Olivia Brayer - Cantor Fitzgerald Stacy Ku - Cowen Ed Arce - H.C. Wainwright Joseph Schwartz - SVB Securities Justin Kim - Oppenheimer Operator Greetings, and we ...